Compare PRLB & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | MDXG |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2012 | N/A |
| Metric | PRLB | MDXG |
|---|---|---|
| Price | $53.65 | $5.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $53.00 | $10.67 |
| AVG Volume (30 Days) | 124.7K | ★ 946.0K |
| Earning Date | 02-06-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.61 | 0.27 |
| Revenue | ★ $518,384,000.00 | $393,442,000.00 |
| Revenue This Year | $7.07 | $19.13 |
| Revenue Next Year | $4.87 | $2.11 |
| P/E Ratio | $90.17 | ★ $20.07 |
| Revenue Growth | 2.82 | ★ 14.77 |
| 52 Week Low | $29.59 | $5.13 |
| 52 Week High | $56.60 | $9.30 |
| Indicator | PRLB | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 23.04 |
| Support Level | $52.95 | $5.15 |
| Resistance Level | $56.60 | $5.45 |
| Average True Range (ATR) | 1.64 | 0.21 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 51.68 | 10.74 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.